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Introduction
There is considerable variability among patients with 
multiple sclerosis (MS), particularly in their response 
to therapy with disease-modifying drugs (DMDs).1–3 
Poorer prognosis for patients with MS can be pre-
dicted by relapses and magnetic resonance imaging 
(MRI) disease activity during treatment.4,5 The com-
bination of clinical and MRI parameters has also been 
used to monitor the response of patients to therapy 
and predict the likelihood of future clinical events and 
worsening of disability.6–9 Assessing the benefit:risk 
balance is key to selecting the appropriate treatment 
for patients, with respect to the risk of future relapses 
or disability worsening.10
Efficacy of Cladribine Tablets (MAVENCLAD®; 
Merck Serono Europe Ltd, London, UK), in patients 
with relapsing MS, has been demonstrated in the 
CLARITY study on the basis of clinical and MRI 
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Abstract
Background: In the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study, Cladribine 
Tablets significantly improved clinical and magnetic resonance imaging (MRI) outcomes (vs placebo) in 
patients with relapsing-remitting multiple sclerosis.
Objective: Describe two clinically relevant definitions for patients with high disease activity (HDA) at 
baseline of the CLARITY study (utility verified in patients receiving placebo) and assess the treatment 
effects of Cladribine Tablets 3.5 mg/kg compared with the overall study population.
Methods: Outcomes of patients randomised to Cladribine Tablets 3.5 mg/kg or placebo were analysed for 
subgroups using HDA definitions based on high relapse activity (HRA; patients with ⩾2 relapses during 
the year prior to study entry, whether on DMD treatment or not) or HRA plus disease activity on treatment 
(HRA + DAT; patients with ⩾2 relapses during the year prior to study entry, whether on DMD treatment 
or not, PLUS patients with ⩾1 relapse during the year prior to study entry while on therapy with other 
DMDs and ⩾1 T1 Gd+ or ⩾9 T2 lesions).
Results: In the overall population, Cladribine Tablets 3.5 mg/kg reduced the risk of 6-month-confirmed 
Expanded Disability Status Scale (EDSS) worsening by 47% vs placebo. A risk reduction of 82% vs 
placebo was seen in both the HRA and HRA + DAT subgroups (vs 19% for non-HRA and 18% for non-
HRA + DAT), indicating greater responsiveness to Cladribine Tablets 3.5 mg/kg in patients with HDA. 
There were consistent results for other efficacy endpoints. The safety profile in HDA patients was consis-
tent with the overall CLARITY population.
Conclusion: Patients with HDA showed clinical and MRI responses to Cladribine Tablets 3.5 mg/kg 
that were generally better than, or at least comparable with, the outcomes seen in the overall CLARITY 
population.
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measurements, or the composite endpoint of no evi-
dence of disease activity (NEDA).11,12 Furthermore, 
the CLARITY Extension study showed that treatment 
with Cladribine Tablets administered as two short (4 or 
5 days) weekly treatments at the start of months 1 and 
2 in each treatment year, followed by no additional 
active treatment produced durable clinical benefits.13 
Patients with relapsing MS who show an increased 
rate of relapse or disability progression can be 
described as having high disease activity (HDA). The 
current manuscript describes definitions of HDA used 
in new post hoc analyses of the CLARITY study. In 
the summary of product characteristics (SmPC) of fin-
golimod and natalizumab, the European Medicines 
Agency (EMA) has previously defined patients with 
HDA as those with ‘rapidly evolving severe relapsing 
remitting multiple sclerosis defined by 2 or more disa-
bling relapses in one year, and with 1 or more 
Gadolinium-enhancing (Gd+) lesions on brain MRI or 
a significant increase in T2 lesion load as compared to 
a previous recent MRI’. The application of such crite-
ria often depends on the availability of repeated clini-
cal or imaging observations, which may unnecessarily 
delay treatment in precisely the patients who most 
need appropriate therapy. Therefore, due to the hetero-
geneity of MS and lack of agreed definitions or con-
sensus for identifying patients with HDA, the current 
analyses were conducted using retrospective informa-
tion on relapses in the year before the CLARITY study 
began and a single baseline MRI scan. Consequently, 
two definitions of HDA were used: one is based on 
relapse rate, which can identify patients with higher 
clinical disease activity, and the other is based on a 
combination of relapse rate and poor response to treat-
ment as assessed by MRI activity, which can identify 
patients with higher overall levels of disease activity.
Therefore, the objectives of this manuscript are to 
describe the two clinically relevant definitions of 
patients with HDA and to verify the utility of the defini-
tions by presenting assessments of clinical activity from 
patients treated with placebo in the CLARITY study. 
The treatment effects of Cladribine Tablets 3.5 mg/kg in 
subgroups of patients, meeting or not meeting the defi-
nitions of HDA in the CLARITY study, are also 
described. Treatment outcomes for the subgroups were 
compared with those for the overall study population 
(comprising both HDA and non-HDA patients).
Methods
The methods and outcomes of the CLARITY study 
have been published previously.11 Briefly, the study 
enrolled male and female patients aged 18–65 years 
with a definite diagnosis of relapsing-remitting 
multiple sclerosis (RRMS) according to the 2005 
McDonald criteria,14 including at least one relapse in 
the last 12 months before study entry, but no relapses 
in the 28 days before entry, neurological lesions 
detectable by MRI consistent with MS, and an 
Expanded Disability Status Scale (EDSS) score of 
0–5.5.
In CLARITY, patients were excluded if they had 
received immunosuppressive therapy at any time 
before study entry or cytokine-based therapy, intrave-
nous immune globulin therapy, or plasmapheresis 
within 3 months before study entry, or if previous 
treatment with two or more DMDs had failed. Eligible 
patients were assigned (1:1:1) to either Cladribine 
Tablets 3.5 mg/kg, 5.25 mg/kg (cumulative dose over 
96 weeks) or matching placebo.
Based on evidence that relapse activity and MRI 
lesions have an influence on disability worsening in 
clinical studies,4–9 the two HDA criteria developed 
were retrospectively applied in order to identify such 
patients and evaluate their response to Cladribine 
Tablets. Because of the better benefit:risk ratio seen 
with the lower dose in the CLARITY study, the cur-
rent retrospective analysis presents data for patients 
randomised to Cladribine Tablets 3.5 mg/kg (N = 433) 
or placebo (N = 437) using the two different HDA 
definitions, based on relapse history, prior treatment 
and MRI characteristics.
Cladribine Tablets were granted marketing authorisa-
tion by the European Commission on 25 August 2017 
for the treatment of highly active relapsing MS as 
defined by clinical or imaging features. The results 
presented in the manuscript correspond to definitions 
of HDA given in the EMA SmPC for the approved 
product that correspond to treatment-naïve patients 
with relapse activity or patients with evidence of dis-
ease activity while on treatment with a DMD.15
Subgroup analyses
Two overlapping sets of criteria were retrospectively 
applied in the analysis of baseline disease characteris-
tics to subdivide patients into HDA groups (Figure 1). 
The first, which is referred to in this manuscript as the 
high relapse activity (HRA) subgroup, comprises 
patients with ⩾2 relapses during the year prior to 
study entry, whether on DMD treatment or not. The 
second, which is referred to as the HRA plus disease 
activity on treatment (HRA + DAT) subgroup, com-
prises patients with ⩾2 relapses during the year prior 
to study entry, whether on DMD treatment or not, and 
patients with ⩾1 relapse and during the year prior to 
study entry while on therapy with other DMDs and 
⩾1 T1 Gd+ or ⩾9 T2 lesions.
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Disease activity determination in placebo-treated 
patients. The utility of these criteria to retrospectively 
identify patients with HDA among patients receiving 
placebo was assessed by examining annualised relapse 
rate (ARR), time to first qualifying relapse and time to 
6-month-confirmed EDSS worsening in this arm of the 
study. If placebo-treated patients who fulfilled the cri-
teria for either HDA definition departed from the clini-
cal behaviour of the overall population (comprising 
both HDA and non-HDA patients) by manifesting evi-
dence of higher disease activity during the first 2 years 
of the study, this was considered verification of the util-
ity of the criteria used to define HDA.
Effect of treatment with Cladribine Tablets in sub-
groups of patients based on HDA definitions. Efficacy 
analyses from CLARITY assessed the overall popula-
tion, the HRA and HRA + DAT subgroups and corre-
sponding non-HRA and non-HRA + DAT subgroups, 
based on time to 6-month-confirmed EDSS worsening, 
ARR, time to first qualifying relapse and the propor-
tion of patients achieving NEDA. Data on 3-month-
confirmed EDSS worsening and MRI outcomes were 
also analysed. Safety data for applicable subgroups and 
comparisons with the overall population are included.
Statistics
All analyses were post hoc and not pre-specified; no mul-
tiplicity adjustments were done to the resulting p-values. 
All comparisons where the p-value was less than 0.05 by 
statistical testing should be regarded as nominally signifi-
cant. The efficacy parameters were analysed by various 
models. Time to first qualifying relapse and time to EDSS 
worsening were analysed by Cox proportional hazards 
model, and Kaplan–Meier estimates are presented. 
Endpoints based on proportions of subjects (NEDA score) 
were analysed by a logistic regression model. Qualifying 
relapse rate was analysed by Poisson regression model 
with fixed effects for treatment and number of relapses in 
the previous year and the log of time on study as the offset 
variable. The cumulative number of lesions was analysed 
by a negative binomial regression model with fixed effects 
for treatment group and study, with baseline number of 
lesions as covariate and with the log of number of scans as 
the offset variable. Subgroup by treatment interaction was 
analysed by Cox proportional hazard model adjusted for 
treatment, subgroup, subgroup-by-treatment interaction 
and baseline values as covariates.
Note that the analyses presented for the overall 
CLARITY population are slightly different to those in 
Figure 1. Definitions used for the HRA and HRA + DAT subgroups.
DMD: disease modifying drug; DAT: disease activity on treatment; HRA: high relapse activity; HRA+DAT: high relapse activity plus 
disease activity on treatment.
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the original publication.11 In the current report, data 
are derived from an integrated database which 
included other studies with Cladribine Tablets; impu-
tation methods were aligned between studies resulting 
in these slight differences.
Results
Baseline demographics and disease characteristics for 
the intent-to-treat (ITT) population are shown in 
Supplementary Table 1 and for the safety population in 
Supplementary Table 2. Apart from characteristics used 
to define the subgroups (i.e. relapses in the 12 months 
before the study, prior use of DMDs and MRI activity), 
patient demographics and other disease characteristics 
at baseline were similar across the subgroups of patients 
who met or did not meet the HRA or HRA + DAT crite-
ria and the overall population of patients. Patients in the 
HRA and HRA + DAT subgroups had shorter disease 
duration at study baseline than the non-HDA counter-
part subgroups and the overall population.
The overall efficacy analysis based on the ITT popu-
lation involved 870 patients randomised to placebo 
(N = 437) or Cladribine Tablets 3.5 mg/kg (N = 433). 
Of those who met the HRA criteria, 131 were ran-
domised to placebo and 130 to Cladribine Tablets 
3.5 mg/kg (Supplementary Table 1). Among the non-
HRA patients, 306 were randomised to placebo and 
303 to Cladribine Tablets 3.5 mg/kg. Of those who 
met the HRA + DAT criteria, 149 were randomised to 
placebo and 140 to Cladribine Tablets 3.5 mg/kg. 
Among the non-HRA + DAT patients, 288 were ran-
domised to placebo and 293 to Cladribine Tablets 
3.5 mg/kg.
Outcomes in subgroups of patients receiving 
placebo in CLARITY
ARR was higher in the placebo-treated HRA and 
HRA + DAT subgroups than in the overall placebo 
population and the placebo-treated groups who did not 
meet these criteria (Table 1). Both time to first qualifying 
relapse and time to 6-month-confirmed EDSS worsen-
ing were shorter for placebo-treated patients in the HRA 
and HRA + DAT subgroups, than in the overall placebo 
population and the placebo-treated groups who did not 
meet these criteria (Table 1). The increased ARR and 
shorter times to relapse and EDSS worsening in these 
placebo-treated patients, highlight the increased rates of 
disease activity in patients retrospectively identified 
using the HRA and HRA + DAT criteria and verify the 
utility of these criteria for assessing the clinical efficacy 
of Cladribine Tablets 3.5 mg/kg in patients with HDA.
Outcomes in subgroups of patients receiving 
Cladribine Tablets 3.5 mg/kg in CLARITY
In the overall CLARITY population (N = 870), 
Cladribine Tablets 3.5 mg/kg reduced the risk of 
6-month-confirmed EDSS worsening by 47% (hazard 
ratio (HR) = 0.53, 95% confidence interval 
(CI) = 0.36–0.79; p = 0.0016) vs placebo (Figure 2). A 
larger risk reduction in time to 6-month-confirmed 
EDSS worsening for Cladribine Tablets 3.5 mg/kg vs 
placebo of 82% was seen in HRA patients and in 
HRA + DAT patients. Interaction p-values indicated 
that this increase was significant (interaction p-val-
ues; p = 0.0036 for HRA vs non-HRA, and p = 0.0037 
for HRA + DAT vs non-HRA + DAT).
The effects of Cladribine Tablets 3.5 mg/kg in patients 
meeting the criteria for HDA were also demonstrated 
for time to 3-month-confirmed EDSS worsening 
(72% risk reduction in both HDA subgroups vs 20% 
for both non-HDA subgroups; see Supplementary 
Figure 1 for details).
For ARR, the relative risk (RR) ratio favoured 
Cladribine Tablets 3.5 mg/kg in the overall population 
(RR = 0.42, 95% CI = 0.33–0.52; p < 0.0001; Figure 3). 
The RR ratios also favoured Cladribine Tablets 3.5 mg/
Table 1. Outcomes in patients treated with placebo in CLARITY (overall and in HRA and HRA + DAT subgroups).
Overall  
N = 437
HRA  
N = 131
Non-HRA 
N = 306
HRA + DAT 
N = 149
Non-HRA + DAT 
N = 288
ARR (95% CI) 0.35 (0.31–0.39) 0.50 (0.41–0.60) 0.29 (0.24–0.34) 0.47 (0.40–0.57) 0.29 (0.24–0.34)
Time to first qualifying relapse 
(20% patients), days (95% CI)
225 (153–280) 127 (84–236) 260 (174–407) 144 (90–237) 260 (156–433)
Time to 6-month-confirmed 
EDSS worsening (10% 
patients), days (95% CI)
245 (127–345) 110 (85–245) 330 (161–497) 162 (85–247) 329 (156–498)
ARR: annualised relapse rate; CI: confidence interval; EDSS: Expanded Disability Status Scale; HRA: high relapse activity; HRA + DAT: high relapse activity 
plus disease activity on treatment.
Percentiles are estimated from a Kaplan–Meier survival curve.
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kg in each HDA subgroup and indicated even larger 
reductions in RR for patients who met the criteria for 
HRA and HRA + DAT compared with the overall popu-
lation. However, the interaction p-values did not reach 
significance (Figure 3). Time to first qualifying relapse 
in the subgroups of patients meeting criteria for HDA 
at baseline are shown in Supplementary Figure 2.
The RR of cumulative new T1 Gd+ lesions for patients 
in both HDA subgroups treated with Cladribine 
Tablets 3.5 mg/kg was low, with strong effects 
observed in each treatment subgroup (Figure 4). 
Similar results were seen for analyses performed for 
active T2 lesions and combined unique lesions (see 
Supplementary Figures 3 and 4).
For assessment of disease-free status, NEDA was 
selected and defined as no relapses, no 3-month-con-
firmed EDSS worsening, no T1 Gd+ lesions and no 
active T2 lesions. Odds ratios (ORs) for the HRA and 
HRA + DAT subgroups were 8.02, 95% CI = 3.93–
16.35; p < 0.0001 and 7.82, 95% CI = 4.03–15.19; 
p < 0.0001, respectively (Figure 5). Observed point 
estimates in HDA subgroups were systematically 
more favourable than the respective non-HDA sub-
groups, although not reaching significance except for 
HRA + DAT (p = 0.0435; Figure 5).
Figure 2. Forest plot of hazard ratio of time to 6-month-confirmed EDSS worsening by HDA subgroup for Cladribine 
Tablets 3.5 mg/kg vs placebo.
EDSS: Expanded Disability Status Scale; HDA: high disease activity; HRA: high relapse activity; HRA+DAT: high relapse activity plus 
disease activity on treatment.
Safety
Overall, review of the safety data for the HRA and 
HRA + DAT subgroups did not reveal evidence for new 
safety findings compared with those described for the 
overall CLARITY population (Table 2).16 Baseline 
demographics and disease characteristics for the safety 
population are shown in Supplementary Table 2. It should 
be noted that the HRA and HRA + DAT subgroups 
included a lower number of patients than the correspond-
ing non-HRA and non-HRA + DAT subgroups; therefore, 
comparisons need to be considered with caution.
Discussion
Disease activity, in both treated or treatment-naïve 
patients with relapsing MS, can be predictive of future 
disease worsening and overall poor prognosis.4,17–20 
Consequently, it is important to study the effects of 
DMDs in patients with HDA who may be at risk for 
poor long-term clinical outcomes. Clinical and MRI 
markers of MS disease activity are of value in assess-
ing the therapeutic effects of DMDs and have been 
used to predict patients at risk of disease worsening and 
disability worsening.4,17,18 Patients included in the 
CLARITY study had at least one relapse in the last 
12 months before study entry, so had active disease, but 
the current analyses further explored the association of 
Multiple Sclerosis Journal 25(6)
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baseline characteristics and treatment outcome.11 The 
HDA subgroups presented in this analysis included 
patients with a wide variety of clinical histories, includ-
ing both treatment-naïve and previously treated patients 
with relapsing MS.
Analysis of the placebo arm in the CLARITY study 
shows that the criteria for the HRA and HRA + DAT 
subgroups can identify patients who are more likely 
to experience both relapses and EDSS worsening. 
Specifically, patients meeting these criteria had 
Figure 3. Forest plot of relative risk of ARR by HDA subgroup for Cladribine Tablets 3.5 mg/kg vs placebo.
ARR: Annualised Relapse Rate; HDA: high disease activity; HRA: high relapse activity; HRA + DAT: high relapse activity plus disease 
activity on treatment.
Figure 4. Forest plot of relative risk of cumulative number of new T1 Gd+ lesions by HDA subgroups for Cladribine 
Tablets 3.5 mg/kg vs placebo.
Gd+; gadolinium enhancing; HDA: high disease activity; HRA: high relapse activity; HRA+DAT: high relapse activity plus disease 
activity on treatment.
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higher ARR and shorter time to first qualifying 
relapse and time to 6-month-confirmed EDSS wors-
ening while on placebo. Treatment with Cladribine 
Tablets 3.5 mg/kg showed clear benefit in the overall 
population and in patients with HDA. Risk of 
6-month-confirmed EDSS worsening was reduced 
by up to 82% in HDA subgroups of patients at 
increased risk of disability worsening. Analysis of 
patients in these CLARITY subgroups also showed 
statistically significant reductions in the risk of 
relapses and in the time to first qualifying relapse. 
Importantly, the efficacy seen in patients with HDA 
was achieved with no additional safety concerns, 
supporting a positive and even better benefit:risk 
profile for Cladribine Tablets in this population 
compared with the overall population.
Figure 5. Forest plot of odds ratio of NEDA score by HDA subgroups for Cladribine Tablets 3.5 mg/kg vs placebo.
Gd+; gadolinium enhancing; HDA: high disease activity; HRA: high relapse activity; HRA+DAT: high relapse activity plus disease 
activity on treatment; NEDA: no evidence of disease activity (defined as no relapses, no 3-month confirmed EDSS worsening, no T1 
Gd+ lesions and no active T2 lesions).
Table 2. Summary of safety data for Cladribine Tablets 3.5 mg/kg by HDA subgroup (safety population).
Characteristic Placebo Cladribine Tablets 3.5 mg/kg
Overall 
N = 433
HRA 
N = 131
HRA + DAT 
N = 148
Overall 
N = 442
HRA 
N = 131
HRA + DAT 
N = 142
Any treatment-
emergent AE, n (%)
317 (73.2) 100 (76.3) 112 (75.7) 359 (81.2) 99 (75.6) 109 (76.8)
95% CI 68.8–77.3 68.1–83.3 67.9–82.3 77.3–84.8 67.3–82.7 68.9–83.4
Any treatment-related 
AE, n (%)
167 (38.6) 53 (40.5) 61 (41.2) 251 (56.8) 68 (51.9) 74 (52.1)
95% CI 34.0–43.3 32.0–49.4 33.2–49.6 52.0–61.5 43.0–60.7 43.6–60.6
Any severe treatment-
emergent AE, n (%)
31 (7.2) 12 (9.2) 17 (11.5) 37 (8.4) 10 (7.6) 10 (7.0)
95% CI 4.9–10.0 4.8–5.5 6.8–17.8 6.0–11.4 3.7–13.6 3.4–12.6
Any serious 
treatment-emergent 
AE, n (%)
32 (7.4) 10 (7.6) 11 (7.4) 44 (10.0) 17 (13.0) 17 (12.0)
95% CI 5.1–10.3 3.7–13.6 3.8–12.9 7.3–13.1 7.7–20.0 7.1–18.5
AE: adverse event; CI: confidence interval; HRA: high relapse activity; HRA + DAT: high relapse activity plus disease activity on 
treatment.
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For patients with a high risk of future events, it is 
important to identify therapeutic options that can 
provide high levels of efficacy, preferably with an 
early onset of effect and without additional safety 
risk. Treatment with Cladribine Tablets has been 
previously shown to produce consistent reductions 
in ARR and provide an early onset of effect based 
on MRI assessments compared with placebo, across 
the spectrum of baseline demographics and disease 
characteristics represented in the CLARITY 
study.21,22 Previous publications from the CLARITY 
study have also included data on treatment out-
comes with Cladribine Tablets in groups of patients 
using alternative definitions of HDA at baseline 
(⩾2 relapses in the previous year and either ⩾1 T1 
Gd+ lesions or ⩾9 T2 lesions at baseline).12
The current definitions of HRA and HRA + DAT, 
with utility verified through examination of their 
ability to identify placebo-treated patients at 
increased risk of relapses or EDSS worsening at the 
study baseline show consistency with the previous 
observations. They also examined a greater range of 
key outcomes in HDA groups compared with the 
earlier publication. Importantly, the use of these def-
initions provides a structured and systematic assess-
ment of the effects of Cladribine Tablets, in patients 
who may be at an increased risk of disability wors-
ening due to HRA or DAT. In particular, both of 
these simple definitions are potentially useful for 
routine clinical practice.
Conclusion
In the CLARITY study, patients identified with two 
clinically relevant HDA criteria showed clinical and 
MRI responses to Cladribine Tablets 3.5 mg/kg that 
were generally better than, or at least comparable 
with, the outcomes seen in the overall CLARITY 
study population. There were statistically significant 
improvements in time to 6-month-confirmed disabil-
ity favouring both HDA subgroups versus patients 
without HDA. The safety profile of Cladribine 
Tablets 3.5 mg/kg in HDA patients is consistent with 
that described for the overall CLARITY population, 
supporting a positive benefit:risk profile for 
Cladribine Tablets in this population of patients with 
HDA. Therefore, treatment with Cladribine Tablets 
3.5 mg/kg demonstrates significant clinical effects 
regardless of which highly active disease population 
is analysed. Treatment with Cladribine Tablets 
3.5 mg/kg also led to consistent results for ARR, 
time to first qualifying relapse, NEDA, time to 
3-month-confirmed disability worsening and MRI 
endpoints for patients with HDA.
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